15 Years, 3 Treatments, 1 Unexpected Result

The ProtecT trial is the most important study ever done in localised prostate cancer — but only if you understand who it actually applies to. After 15 years of follow-up on 1,643 men randomly assigned to active monitoring, surgery, or radiotherapy, the headline result was clear: survival was nearly identical across all three arms. But the trial enrolled almost exclusively men with ISUP 1 and ISUP 2 disease — meaning these findings apply to low and favourable intermediate-risk cancer, not to higher-grade disease. In this video, Associate Professor Charles Chabert (Director, The Prostate Clinic, Gold Coast) walks through the 15-year ProtecT data, the critical ISUP caveat, the metastasis gap, the quality-of-life trade-offs, and his honest verdict on who should choose which path. 5 Questions To Ask Your Specialist: What's my ISUP grade group and risk category? What does my MRI show — PIRADS score, lesion size, extracapsular extension? What's my PSA density? If active surveillance is on the table, what's the monitoring schedule and what triggers a switch to treatment? Based on my numbers, what would you recommend if I were your father or brother? I hope this helps and good luck with your journey! ▶️ Visit my website www.prostates.com.au ▶️ Download free urology text book https://prostates.com.au/wp-content/u... Dr Chabert is a board certified urologist specialising in diseases of the prostate, including BPH and prostate cancer. Dr Chabert consults form the following offices: Suite 501, Level 5 Pindara Specialist Suites 29 Carrara St Benowa QLD 4217 Phone: 07 5597 6293 Fax: 07 5539 6879 Email: [email protected] instagram: prostates.com.au   / theprostateclinic   https://prostates.com.au https://prostates.com.au/robotic-pros... https://prostates.com.au/prostate-can... #urology #prostate #prostatecancer #prostatecancermanagement #BPH